Summary
Human peripheral blood monocytes cocultured with tumour cells were used as an in vitro model of in situ interactions between tumour-infiltrating macrophages and the tumour. Tumour cells stimulated de novo expression of the human tumour necrosis factor α (TNF) gene in monocytes and caused the release of TNF into the culture supernatant. A group of 14 patients with stage IVA gastric cancer receiving adjuvant chemotherapy (5-FU, Adriamycin, mitomycin C: FAM) or immunochemotherapy (BCG+FAM) was investigated for the ability of monocytes to produce TNF in vitro upon stimulation with tumour cells or purified protein derivative of tuberculin (PPD). Patients were followed at biweekly intervals, i.e. before each instillation of BCG epicutaneously over a period of 10 weeks. It was found that monocytes of some patients receiving BCG at the end of the observation period had an enhanced ability to produce TNF following stimulation with tumour cells. In contrast, such production was not substantially altered during the study period in patients on chemotherapy. PPD-induced TNF production was much weaker and was not significantly changed during this observation time. We infer that BCG immunotherapy may induce the subtle changes in some cancer patients that lead to an increased interaction between monocytes and tumour cells and result in enhanced production of cytokine(s) with antitumour properties.
Similar content being viewed by others
References
Aderka D, Fisher S, Levo Y Holtmann H, Halm T, Wallach D (1985) Cachectin-tumour necrosis factor production by cancer patients. Lancet ii: 1190
Balkwill F, Burke F, Talbot D, Travernier J, Osborne S, Naylor S, Durbin H, Fiers W (1987) Evidence for tumour necrosis factor-cachectin production in cancer. Lancet 1229: 32
Beissert S, Bergholz M, Waase I, Lepsien G, Schauer A, Pfizenmaier K, Kronke M (1989) Regulation of tumour necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc Natl Acad Sci USA 86: 5064
Bohle A, Nowc CH, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD (1990) Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma. Cytokine 2: 175
Editorial (1991) Topical BCG for recurrent superficial bladder cancer. Lancet 337: 821
Fielding JWL, Rogonski C, Jones BG, Powell J, Waterhouse JA, Brookes WS (1984) Clinicophathological staging of gastric cancer. Br J Surg 71: 677
Florentin I, Brulej-Rosset M, Davigny M, Mathe G (1978) Comparison of the effects of BCG and a preparation of heat-killedPseudomonas aeruginosa on the immune responses in mice. In: Werner GH, Floch F (eds) The pharmacology of immunoregulation. Academic Press, London, p 335
Hasday JD, Shah EM, Lieberman AP (1990) Macrophage tumor necrosis factor-alfa release is induced by contact with some tumors. J Immunol 145: 371
Janicke R, Mannel DN (1990) Distinct tumor cell membrane constitutents activate human monocytes for tumor necrosis factor synthesis. J Immunol 144: 1144
MacDonald JS, Schein PS, Wolley PV, Smythe P, Ueno W, Hoth D, Smith F, Bairon M, Gisselbrecht Ch, Brunet R, Lagarde C (1980) 5-Flourouracil, doxorubicin, mitomycin C (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533
Mosmann T (1985) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55
Mytar B, Zembala M, Uracz W, Czupryna A (1982) Cytostatic activity on tumour cells of monocytes from patients with gastrointestinal cancer. Cancer Immunol Immunother 13: 190
Naylor SM, Malik STA, Stamp GWH, Jobling T, Balkwill FR (1990) In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer 26: 1027
Ochiai T, Sato H, Hayashi R, Asano T, Sato H, Yamamura Y (1983) Postoperative adjuvant immunotherapy of gastric cancer with BCG cell wall skeleton. Cancer Immunol Immunother 14: 167
Popiela T, Zembala M, Oszacki J, Jedrychowski W (1982) A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advanced gastric cancer. Cancer Immunol Immunother 13: 182
Popiela T, Zembala M, Kulig J, Czupryna A, Uracz W (1988) Postoperative immunochemotherapy (BCG+5-FU) in advanced gastric cancer. Anticancer Res 8: 1423
Socher SH, Martinez D, Craig JB, Kulm JF, Uliff A (1988) Tumour necrosis factor not detectable in patients with clinical cancer cachexia. INCI 80: 595
Wallis RS, Fujiwara H, Ellner JJ (1986) Direct stimulation of monocyte release of interleukin-1 by mycobacterial protein antigens. J Immunol 136: 193
Wallis RS, Amir-Tahmasseb M, Ellner JJ (1990) Induction of interleukin-1 and tumour necrosis factor by mycobacterial proteins: the monocyte western blot. Proc Natl Acad Sci USA 87: 3348
Wong GH, Goeddel D (1989) Tumour necrosis factor. In: Zembala M, Asherson GL (eds) human monocytes. Academic Press, London, p 195
Zembala M, Buckle AM (1989) Monocytes in malignant disease. In: Zembala M, Asherson GL (eds) Human monocytes. Academic Press, London, p 513
Zembala M, Mytar B, Ruggiero I, Uracz W, Popiela T, Czupryna A (1983) Suppressor cells and survival of patients with advanced gastric cancer. J NCI 70: 223
Zembala M, Mytar B, Woloszyn M, Popiela T, Uracz W, Czupryna A (1988) Monocyte TNF production in gastrointestinal cancer. Lancet ii: 1262
Zembala M, Kowalczyk D, Pryjma J, Ruggiero I, Mytar B, Klysik J, Stec WJ (1990) The role of tumour necrosis factor in the regulation of antigen presentation by human monocytes. Intern Immunol 2: 337
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zembala, M., Czupryna, A., Wieckiewicz, J. et al. Tumour-cell-induced production of tumour necrosis factor by monocytes of gastric cancer patients receiving BCG immunotherapy. Cancer Immunol Immunother 36, 127–132 (1993). https://doi.org/10.1007/BF01754413
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01754413